BROCHURE: ALPHA-1 DEEP DIVE
This brochure contains information about the genetic disorder known as alpha-1 antitrypsin deficiency (A1AD). A1AD is a disorder, not a disease, but can cause disease in some people.
This brochure contains information about the genetic disorder known as alpha-1 antitrypsin deficiency (A1AD). A1AD is a disorder, not a disease, but can cause disease in some people.
Panniculitis is a very rare but treatable condition, sometimes related to A1AD. Its estimated prevalence is one in 1,000 patients with the Pi*ZZ A1AD genotype.
A1AD is a common genetic (inherited) disorder associated with low levels of a natural protein known as Alpha-1 Antitrypsin (AAT). Low levels of AAT can cause a number of diseases.
A1AD is a complicated and sometimes challenging diagnosis. Not everyone with abnormal Alpha-1 Antitrypsin Deficiency (AAT) is affected by the deficiency.
You are likely to have a lot of questions following a diagnosis of Alpha-1 Antitrypsin Deficiency (A1AD). Select the questions in the attachment that best relate to you.
There is only one treatment available to protect the lungs of people with A1AD. The treatment is Alpha-1 proteinase inhibitor (also called Augmentation Therapy).
A position paper from Gaynor Heading PhD (Med), President of Alpha-1 Organisation Australia, focusing on preventing harm and saving lives for individuals with A1AD.
There are several types of devices that provide medical grade oxygen, all of which provide oxygen to the lungs via tubing and mask / cannula or similar facial device.